Estrogen Analogues: Selective Estrogen Receptor Modulators and Phytoestrogens

Osteoporosis, Two-Volume Set

Volumn , Issue , 2008, Pages 1705-1723

  Prince, Richard ^a   Muchmore, Douglas B ^b   Siris, Ethel S ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ELI LILLY AND COMPANY   (United States)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955454685     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370544-0.50075-6     Document Type: Chapter

References (110)

1. Draper C.R., Edel M.J., Dick I.M., Randall A.G., Martin G.B., Prince R.L. Phytoestrogens reduce bone loss and bone resorption in oophorectomized rats. J Nutr 1997, 127(9):1795-1799.
2. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996, 273(5279):1222-1225.
3. Vanacker J.M., Pettersson K., Gustafsson J.A., Laudet V. EMBO J 1999, 18(15):4270-4279.
4. Shutt D.A., Cox R.I. Steroid and phyto-oestrogen binding to sheep uterine receptors in vitro. J Endocrinol 1972, 52(2):299-310.
5. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138(3):863-870.
6. Casanova M., You L., Gaido K.W., Archibeque-Engle S., Janszen D.B., Heck H.A. Developmental effects of dietary phytoestrogens in Sprague-Dawley rats and interactions of genistein and daidzein with rat estrogen receptors alpha and beta in vitro. Toxicol Sci 1999, 51(2):236-244.
7. Lampe J.W., Martini M.C., Kurzer M.S., Adlercreutz H., Slavin J.L. Urinary lignan and isoflavonoid excretion in premenopausal women consuming flaxseed powder. Am J Clin Nutr 1994, 60(1):122-128.
8. Sathyamoorthy N., Wang T.T., Phang J.M. Stimulation of pS2 expression by diet-derived compounds. Cancer Res 1994, 54(4):957-961.
9. Mueller S.O., Simon S., Chae K., Metzler M., Korach K.S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor {alpha} (ER{alpha}) and ER{beta} in human cells. Toxicol Sci 2004, 80(1):14-25.
10. Moriarty K., Kim K.H., Bender J.R. Minireview: Estrogen receptor-mediated rapid signaling. Endocrinology 2006, 147(12):5557-5563.
11. Pike A.C., Brzozowski A.M., Hubbard R.E., Bonn T., Thorsell A.G., Engstrom O., Ljunggren J., Gustafsson J.A., Carlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999, 18(17):4608-4618.
12. Pike A.C., Brzozowski A.M., Walton J., Hubbard R.E., Bonn T., Gustafsson J.A., Carlquist M. Structural aspects of agonism and antagonism in the oestrogen receptor. Biochem Soc Trans 2000, 28(4):396-400.
13. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389(6652):753-758.
14. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95(7):927-937.
15. Danielian P.S., White R., Lees J.A., Parker M.G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 1992, 11(3):1025-1033.
16. Montano M.M., Ekena K., Krueger K.D., Keller A.L., Katzenellenbogen B.S. Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 1996, 10(3):230-242.
17. Nichols M., Rientjes J.M., Stewart A.F. Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO J 1998, 17(3):765-773.
18. Levenson A.S., Jordan V.C. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 1998, 58(9):1872-1875.
19. Levenson A.S., Catherino W.H., Jordan V.C. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 1997, 60(5-6):261-268.
20. Watanabe T., Inoue S., Ogawa S., Ishii Y., Hiroi H., Ikeda K., Orimo A., Muramatsu M. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: Functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 1997, 236(1):140-145.
21. Smith C.L., O'Malley B.W. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004, 25(1):45-71.
22. McKenna N.J., Xu J., Nawaz Z., Tsai S.Y., Tsai M.J., O'Malley B.W. Nuclear receptor coactivators: Multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 1999, 69(1-6):3-12.
23. Paige L.A., Christensen D.J., Gron H., Norris J.D., Gottlin E.B., Padilla K.M., Chang C.Y., Ballas L.M., Hamilton P.T., McDonnell D.P., Fowlkes D.M. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci USA 1999, 96(7):3999-4004.
24. McDonnell D.P., Clemm D.L., Hermann T., Goldman M.E., Pike J.W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995, 9(6):659-669.
25. Norris J.D., Paige L.A., Christensen D.J., Chang C.Y., Huacani M.R., Fan D., Hamilton P.T., Fowlkes D.M., McDonnell D.P. Peptide antagonists of the human estrogen receptor. Science 1999, 285(5428):744-746.
26. Routledge E.J., White R., Parker M.G., Sumpter J.P. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. J Biol Chem 2000, 275(46):35986-35993.
27. Rickard D.J., Monroe D.G., Ruesink T.J., Khosla S., Riggs B.L., Spelsberg T.C. Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta. J Cell Biochem 2003, 89(3):633-646.
28. Mueller S.O., Simon S., Chae K., Metzler M., Korach K.S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004, 80(1):14-25.
29. Elgort M.G., Zou A., Marschke K.B., Allegretto E.A. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-alpha 1 promoter via a novel sequence. Mol Endocrinol 1996, 10(5):477-487.
30. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277(5331):1508-1510.
31. McInerney E.M., Weis K.E., Sun J., Mosselman S., Katzenellenbogen B.S. Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 1998, 139(11):4513-4522.
32. Sun J., Meyers M.J., Fink B.E., Rajendran R., Katzenellenbogen J.A., Katzenellenbogen B.S. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 1999, 140(2):800-804.
33. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., Han K., DiGregorio G.B., Katzenellenbogen J.A., Katzenellenbogen B.S., Roberson P.K., Weinstein R.S., Jilka R.L., Manolagas C. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001, 104:719-730.
34. Ibrahim A.R., Abul-Hajj Y.J. Aromatase inhibition by flavonoids. J Steroid Biochem Mol Biol 1990, 37(2):257-260.
35. Adlercreutz H., Bannwart C., Wahala K., Makela T., Brunow G., Hase T., Arosemena P.J., Kellis J.T., Vickery L.E. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 1993, 44(2):147-153.
36. Wang C., Makela T., Hase T., Adlercreutz H., Kurzer M.S. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 1994, 50(3-4):205-212.
37. Keung W.M. Dietary estrogenic isoflavones are potent inhibitors of beta-hydroxysteroid dehydrogenase of P. testosteronii. Biochem Biophys Res Commun 1995, 215(3):1137-1144.
38. Evans B.A., Griffiths K., Morton M.S. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995, 147(2):295-302.
39. Le Bail J.C., Champavier Y., Chulia A.J., Habrioux G. Effects of phytoestrogens on aromatase, 3beta and 17betahydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sci 2000, 66(14):1281-1291.
40. Loukovaara M., Carson M., Palotie A., Adlercreutz H. Regulation of sex hormone-binding globulin production by isoflavonoids and patterns of isoflavonoid conjugation in HepG2 cell cultures. Steroids 1995, 60(9):656-661.
41. Jha H.C., von Recklinghausen G., Zilliken F. Inhibition of in vitro microsomal lipid peroxidation by isoflavonoids. Biochem Pharmacol 1985, 34(9):1367-1369.
42. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987, 262(12):5592-5595.
43. Degen G.H. Interaction of phytoestrogens and other environmental estrogens with prostaglandin synthase in vitro. J Steroid Biochem 1990, 35(3-4):473-479.
44. Wang H., Peters G.A., Zeng X., Tang M., Ip W., Khan S.A. Yeast two-hybrid system demonstrates that estrogen receptor dimerization is ligand-dependent in vivo. J Biol Chem 1995, 270(40):23322-23329.
45. Stewart P.J., Stern P.H. Effects of the antiestrogens tamoxifen and clomiphene on bone resorption in vitro. Endocrinology 1986, 118(1):125-131.
46. Feldmann S., Minne H.W., Parvizi S., Pfeifer M., Lempert U.G., Bauss F., Ziegler R. Antiestrogen and antiandrogen administration reduce bone mass in the rat. Bone Miner 1989, 7(3):245-254.
47. Turner R.T., Wakley G.K., Hannon K.S., Bell N.H. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 1987, 2(5):449-456.
48. Goulding A., Gold E., Fisher L. Effects of clomiphene and tamoxifen in vivo on the bone-resorbing effects of parathyroid hormone and of high oral doses of calcitriol(1,25(OH)2D3) in rats with intact ovarian function consuming low calcium diet. Bone Miner 1990, 8:185-193.
49. Turner R.T., Wakley G.K., Hannon K.S., Bell N.H. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 1988, 122(3):1146-1150.
50. Perry M.J., Gujra S., Whitworth T., Tobias J.H. Tamoxifen stimulates cancellous bone formation in long bones of female mice. Endocrinology 2005, 146(3):1060-1065.
51. Black L.J., Sato M., Rowley E.R., Magee D.E., Bekele A., Williams D.C., Cullinan G.J., Bendele R., Kauffman R.F., Bensch W.R., et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994, 93(1):63-69.
52. Sato M., Kim J., Short L.L., Slemenda C.W., Bryant H.U. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther 1995, 272(3):1252-1259.
53. Evans G.L., Bryant H.U., Magee D.E., Turner R.T. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 1996, 137(10):4139-4144.
54. Evans G., Bryant H.U., Magee D., Sato M., Turner R.T. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994, 134(5):2283-2288.
55. Jerome C., Lees C.J. Raloxifene increases bone mass and reduces bone turnover in ovariectomized cynomolgous monkeys. J Bone Miner Res 1996, 11(Suppl. 1):S445.
56. Frolik C.A., Bryant H.U., Black E.C., Magee D.E., Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 1996, 18(6):621-627.
57. Helvering L.M., Liu R., Kulkarni N.H., Wei T., Chen P., Huang S., Lawrence F., Halladay D.L., Miles R.R., Ambrose E.M., Sato M., Ma Y.L., Frolik C.A., Dow E.R., Bryant H.U., Onyia J.E. Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene. Mol Pharmacol 2005, 68(5):1225-1238.
58. Turner C.H., Sato M., Bryant H.U. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994, 135(5):2001-2005.
59. Ma Y.L., Bryant H.U., Zeng Q., Palkowitz A., Jee W.S., Turner C.H., Sato M. Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res 2002, 17(12):2256-2264.
60. Kajiya H., Okabe K., Okamoto F., Tsuzuki T., Soeda H. Protein tyrosine kinase inhibitors increase cytosolic calcium and inhibit actin organization as resorbing activity in rat osteoclasts. J Cell Physiol 2000, 183(1):83-90.
61. Gao Y.H., Yamaguchi M. Suppressive effect of genistein on rat bone osteoclasts: Apoptosis is induced through Ca2+ signaling. Biol Pharm Bull 1999, 22(8):805-809.
62. Gao Y.H., Yamaguchi M. Anabolic effect of daidzein on cortical bone in tissue culture: Comparison with genistein effect. Mol Cell Biochem 1999, 194(1-2):93-97.
63. Yamaguchi M., Gao Y.H. Anabolic effect of genistein and genistin on bone metabolism in the femoral-metaphyseal tissues of elderly rats: The genistein effect is enhanced by zinc. Mol Cell Biochem 1998, 178(1-2):377-382.
64. Fanti P., Monier-Faugere M.C., Geng Z., Schmidt J., Morris P.E., Cohen D., Malluche H.H. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int 1998, 8(3):274-281.
65. Arjmandi B.H., Getlinger M.J., Goyal N.V., Alekel L., Hasler C.M., Juma S., Drum M.L., Hollis B.W., Kukreja S.C. Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats. Am J Clin Nutr 1998, 68(6 Suppl):1358S-1363S.
66. Arjmandi B.H., Birnbaum R., Goyal N.V., Getlinger M.J., Juma S., Alekel L., Hasler C.M., Drum M.L., Hollis B.W., Kukreja S.C. Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr 1998, 68(6 Suppl):1364S-1368S.
67. Thigpen J.E., Setchell K.D., Ahlmark K.B., Locklear J., Spahr T., Caviness G.F., Goelz M.F., Haseman J.K., Newbold R.R., Forsythe D.B. Phytoestrogen content of purified, open and closed-formula laboratory animal diets. Lab Anim Sci 1999, 49(5):530-536.
68. Ishimi Y., Arai N., Wang X., Wu J., Umegaki K., Miyaura C., Takeda A., Ikegami S. Difference in effective dosage of genistein on bone and uterus in ovariectomized mice. Biochem Biophys Res Commun 2000, 274(3):697-701.
69. Ishimi Y., Miyaura C., Ohmura M., Onoe Y., Sato T., Uchiyama Y., Ito M., Wang X., Suda T., Ikegami S. Endocrinology 1999, 140(4):1893-1900.
70. Anderson J.J., Ambrose W.W., Garner S.C. Biphasic effects of genistein on bone tissue in the ovariectomized, lactating rat model. Proc Soc Exp Biol Med 1998, 217(3):345-350.
71. Power K.A., Ward W.E., Chen J.M., Saarinen N.M., Thompson L.U. Genistein alone and in combination with the mammalian lignans enterolactone and enterodiol induce estrogenic effects on bone and uterus in a postmenopausal breast cancer mouse model. Bone 2006, 39(1):117-124.
72. Toda T., Uesugi T., Hirai K., Nukaya H., Tsuji K., Ishida H. New 6-O-acyl isoflavone glycosides from soybeans fermented with Bacillus subtilis (natto): I. 6-O-succinylated isoflavone glycosides and their preventive effects on bone loss in ovariectomized rats fed a calcium-deficient diet. Biol Pharm Bull 1999, 22(11):1193-1201.
73. Yamaguchi M., Kakuda H., Gao Y.H., Tsukamoto Y. Prolonged intake of fermented soybean (natto) diets containing vitamin K2 (menaquinone-7) prevents bone loss in ovariectomized rats. J Bone Miner Metab 2000, 18(2):71-76.
74. Tsutsumi N. Effect of coumestrol on bone metabolism in organ culture. Biol Pharm Bull 1995, 18(7):1012-1015.
75. Dodge J.A., Glasebrook A.L., Magee D.E., Phillips D.L., Sato M., Short L.L., Bryant H.U. Environmental estrogens: Effects on cholesterol lowering and bone in the ovariectomized rat. J Steroid Biochem Mol Biol 1996, 59(2):155-161.
76. Li H., Li J., Prasain J.K., Tezuka Y., Namba T., Miyahara T., Tonami S., Seto H., Tada T., Kadota S. Antiosteoporotic activity of the stems of Sambucus sieboldiana. Biol Pharm Bull 1998, 21(6):594-598.
77. Jiu L.J., Morikawa N., Omi N., Ezawa I. The effect of tochu bark on bone metabolism in the rat model with ovariectomized osteoporosis. J Nutr Sci Vitaminol (Tokyo) 1994, 40(3):261-273.
78. Miyamoto M., Matsushita Y., Kiyokawa A., Fukuda C., Iijima Y., Sugano M., Akiyama T. Prenylflavonoids: A new class of non-steroidal phytoestrogen (Part 2). Estrogenic effects of 8-isopentenylnaringenin on bone metabolism. Planta Med 1998, 64(6):516-519.
79. Cole M.P., Jones C.T., Todd I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971, 25(2):270-275.
80. Christakos S., Prince R. Estrogen, D vitamin, and calcium transport. J Bone Miner Res 2003, 18(10):1737-1739.
81. Heaney R.P., Draper M.W. Raloxifene and estrogen: Comparative bone-remodeling kinetics. J Clin Endocrinol Metab 1997, 82(10):3425-3429.
82. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337(23):1641-1647.
83. Meunier P.J., Vignot E., Garnero P., Confavreux E., Paris E., Liu-Leage S., Sarkar S., Liu T., Wong M., Draper M.W. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 1999, 10(4):330-336.
84. Lufkin E.G., Whitaker M.D., Nickelsen T., Argueta R., Caplan R.H., Knickerbocker R.K., Riggs B.L. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Miner Res 1998, 13(11):1747-1754.
85. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Gluer C.C., Krueger K., Cohen J., Eckert S., Ensrud E., Avioli L.V., Lips P., Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645.
86. Johnston C.C., Bjarnason N.H., Cohen F.J., Shah A., Lindsay R., Mitlak B.H., Huster W., Draper M.W., Harper K.D., Heath 3rd H., Gennari C., Christiansen C., Arnaud C.D., Delmas P.D. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 doubleblind, randomized, placebo-controlled trials. Arch Intern Med 2000, 160(22):3444-3450.
87. Kung A.W., Chao H.T., Huang K.E., Need A.G., Taechakraichana N., Loh F.H., Gonzaga F., Sriram U., Ismail N.M., Farooqi A., Rachman I.A., Crans G.G., Wong M., Thiebaud D. Efficacy and safety of raloxifene 60 milligrams/ day in postmenopausal Asian women. J Clin Endocrinol Metab 2003, 88(7):3130-3136.
88. Zheng S., Wu Y., Zhang Z., Yang X., Hui Y., Zhang Y., Chen S., Deng W., Liu H., Ekangaki A., Stocks J., Harper K., Liu J. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: A randomized clinical trial in Beijing. Chin Med J (Engl) 2003, 116(8):1127-1133.
89. Morii H., Ohashi Y., Taketani Y., Fukunaga M., Nakamura T., Itabashi A., Sarkar S., Harper K. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: Results from a randomized placebo-controlled trial. Osteoporos Int 2003, 14(10):793-800.
90. Jolly E.E., Bjarnason N.H., Neven P., Plouffe L., Johnston C.C., Watts S.D., Arnaud C.D., Mason T.M., Crans G., Akers R., Draper M.W. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003, 10(4):337-344.
91. Siris E.S., Harris S.T., Eastell R., Zanchetta J.R., Goemaere S., Diez-Perez A., Stock J.L., Song J., Qu Y., Kulkarni P.M., Siddhanti S.R., Wong M., Cummings S.R. Skeletal effects of raloxifene after 8 years: Results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2005, 20(9):1514-1524.
92. Johnell O., Scheele W.H., Lu Y., Reginster J.Y., Need A.G., Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87(3):985-992.
93. Genant H.K., Lang T., Fuerst T., Pinette K.V., Zhou C., Thiebaud D., Diez-Perez A. Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography. Bone 2004, 35(5):1164-1168.
94. Boivin G., Lips P., Ott S.M., Harper K.D., Sarkar S., Pinette K.V., Meunier P.J. Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 2003, 88(9):4199-4205.
95. Weinstein R.S., Parfitt A.M., et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003, 14:814-822.
96. Maricic M., Adachi J.D., Sarkar S., Wu W., Wong M., Harper K.D. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002, 162(10):1140-1143.
97. Barrett-Connor E., Mosca L., Collins P., Geiger M.J., Grady D., Kornitzer M., McNabb M.A., Wenger N.K. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355(2):125-137.
98. Cauley J.A., Norton L., Lippman M.E., Eckert S., Krueger K.A., Purdie D.W., Farrerons J., Karasik A., Mellstrom D., Ng K.W., Stepan J.J., Powles T.J., Morrow M., Costa A., Silfen S.L., Walls E.L., Schmitt H., Muchmore D.B., Jordan C., Ste-Marie L.G. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat 2001, 65(2):125-134.
99. Martino S., Cauley J.A., Barrett-Connor E., Powles T.J., Mershon J., Disch D., Secrest R.J., Cummings S.R. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96(23):1751-1761.
100. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., Bevers T.B., Fehrenbacher L., Pajon E.R., Wade J.L., Robidoux A., Margolese R.G., James J., Lippman S.M., Runowicz C.D., Ganz P.A., Reis S.E., McCaskill-Stevens W., Ford L.G., Jordan V.C., Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295(23):2727-2741.
101. Kanis J.A., Borgstrom F., Johnell O., Oden A., Sykes D., Jonsson B. Cost-effectiveness of raloxifene in the UK: An economic evaluation based on the MORE study. Osteoporos Int 2005, 16(1):15-25.
102. McClung M.R., Siris E., Cummings S., Bolognese M., Ettinger M., Moffett A., Emkey R., Day W., Somayaji V., Lee A. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006, 13(3):377-386.
103. Kelly G.E., Nelson C., Waring M.A., Joannou G.E., Reeder A.Y. Metabolites of dietary (soya) isoflavones in human urine. Clin Chim Acta 1993, 223(1-2):9-22.
104. Atkinson C., Frankenfeld C.L., Lampe J.W. Gut bacterial metabolism of the soy isoflavone daidzein: Exploring the relevance to human health. Exp Biol Med (Maywood) 2005, 230(3):155-170.
105. Xu X., Wang H.J., Murphy P.A., Cook L., Hendrich S. Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women. J Nutr 1994, 124(6):825-832.
106. Potter S.M., Baum J.A., Teng H., Stillman R.J., Shay N.F., Erdman J.W. Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998, 68(6 Suppl):1375S-1379S.
107. Atkinson C., Compston J.E., Day N.E., Dowsett M., Bingham S.A. The effects of phytoestrogen isoflavones on bone density in women: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2004, 79(2):326-333.
108. Kreijkamp-Kaspers S., Kok L., Grobbee D.E., de Haan E.H., Aleman A., Lampe J.W., van der Schouw Y.T. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: A randomized controlled trial. JAMA 2004, 292(1):65-74.
109. Alexandersen P., Toussaint A., Christiansen C., Devogelaer J.P., Roux C., Fechtenbaum J., Gennari C., Reginster J.Y. Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial. JAMA 2001, 285(11):1482-1488.
110. Kardinaal A.F., Morton M.S., Bruggemann-Rotgans I.E., van Beresteijn E.C. Phyto-oestrogen excretion and rate of bone loss in postmenopausal women. Eur J Clin Nutr 1998, 52(11):850-855.